AGM report

I attended the AGM in Sydney today but will not be able to write a full report until Sunday. There is much to cover.

Some teasers

1. The DARRT program remains on track for a registration trial starting in 2019, but it sounds like a discovery about sarcoma treatment might lead to a faster route to FDA approval. IIRC a compassionate patient was treated for a sarcoma about 12 months ago.

2. It is quite clear that Veyonda has achieved great results in the LuPIN trial. The data will not be released by the trial investigators until 2019, but at $10,000 plus per patient (the cost to Noxopharm) there is no way NOX would have agreed to a doubling of numbers unless good things were happening.

3. In patients who would otherwise die within six months, stable disease is a great result. A high proportion of Veyonda patients have experienced stable disease or better over an extended period.

4. Graham Kelly has assembled a great team of scientists and collaborators.

5. Professor Nat Lenzo from Theranostics gave a brilliant presentation. Watch this space.

It was a GREAT meeting